{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:41:15Z","timestamp":1787622075627,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Vitiligo ist mit einer Pr\u00e4valenz von 0,5\u20132,0\u202f% eine der weltweit h\u00e4ufigsten Hauterkrankungen mit einem Verlust des Pigments. Die Hauterkrankung hat einen entstellenden, oft stigmatisierenden Charakter und ist oft mit psychosozialen Belastungen assoziiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Zielsetzung<\/jats:title>\n                <jats:p>Es erfolgt eine \u00dcbersicht \u00fcber die psychosoziale Beeintr\u00e4chtigung, Krankheitslast und den resultierenden Versorgungsbedarf von Patienten mit Vitiligo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Es handelt sich um eine narrative \u00dcbersichtsarbeit auf der Grundlage einer Literaturrecherche in PubMed f\u00fcr die Jahre 1996 bis 2022 zu den Themen Krankheitslast, Lebensqualit\u00e4t und Stigmatisierung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Recherche ergab f\u00fcr den Suchzeitraum 175 relevante Originalarbeiten inklusive klinischer Studien, Metaanalysen und systematischer \u00dcbersichtsarbeiten (<jats:italic>n<\/jats:italic>\u202f=\u200965). Dabei dokumentiert eine Vielzahl an Studien, dass Vitiligo bei den Betroffenen mit erheblichen psychosozialen Belastungen und relevanten Einbu\u00dfen an Lebensqualit\u00e4t einhergeht. Problembereiche betreffen insbesondere Stigmatisierung, sexuelle Funktionsst\u00f6rungen, Angst, vermindertes Selbstwertgef\u00fchl und Probleme im Beruf. Das beobachtete erh\u00f6hte Ausma\u00df von Angst und Depressionen korreliert mit der Schwere und Aktivit\u00e4t der Vitiligo. Oft tr\u00e4gt auch Komorbidit\u00e4t zur weiteren Krankheitslast bei. Diese Faktoren determinieren bei einem relevanten Teil der Betroffenen einen hohen Versorgungsbedarf.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die Vitiligo stellt nicht in erster Linie ein kosmetisches Problem dar, sondern eine behandlungsbed\u00fcrftige Erkrankung im Sinne der Definition der Weltgesundheitsorganisation von Gesundheit als k\u00f6rperliches, geistiges und soziales Wohlbefinden. Die Nutzen von Behandlungsoptionen sind an ihren Effekten auf patientenberichtete Endpunkte zu messen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00105-024-05312-z","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T13:03:02Z","timestamp":1710162182000},"page":"404-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lebensqualit\u00e4t, Krankheitslast und Versorgungsbedarf von Patienten mit Vitiligo","Quality of life, disease burden and healthcare need of patients with vitiligo"],"prefix":"10.1007","volume":"75","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gewiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Ben-Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"5312_CR1","doi-asserted-by":"publisher","first-page":"e13215","DOI":"10.1111\/dth.13215","volume":"33","author":"K Agarwal","year":"2020","unstructured":"Agarwal\u00a0K, Podder\u00a0I, Kassir\u00a0M et\u00a0al (2020) Therapeutic options in vitiligo with special emphasis on immunomodulators: a\u00a0comprehensive update with review of literature. Dermatol Ther 33:e13215","journal-title":"Dermatol Ther"},{"key":"5312_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.25259\/IJDVL_928_20","volume":"88","author":"S Agrawal","year":"2021","unstructured":"Agrawal\u00a0S, Satapathy\u00a0S, Gupta\u00a0V et\u00a0al (2021) Family vitiligo impact scale: a\u00a0scale to measure the quality-of-life of family members of patients with vitiligo. Indian J Dermatol Venereol Leprol 88:32\u201339","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"5312_CR3","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/jdv.15168","volume":"32","author":"A Ahmed","year":"2018","unstructured":"Ahmed\u00a0A, Steed\u00a0L, Burden-Teh\u00a0E et\u00a0al (2018) Identifying key components for a\u00a0psychological intervention for people with vitiligo\u2014a\u00a0quantitative and qualitative study in the United Kingdom using web-based questionnaires of people with vitiligo and healthcare professionals. J\u00a0Eur Acad Dermatol Venereol 32:2275\u20132283","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ijd.13198","volume":"55","author":"AA Amer","year":"2016","unstructured":"Amer\u00a0AA, Gao\u00a0XH (2016) Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol 55:608\u2013614","journal-title":"Int J Dermatol"},{"key":"5312_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000350555","volume":"44","author":"M Augustin","year":"2013","unstructured":"Augustin\u00a0M (2013) Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 44:74\u201381","journal-title":"Curr Probl Dermatol"},{"key":"5312_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000128992","volume":"217","author":"M Augustin","year":"2008","unstructured":"Augustin\u00a0M, Gajur\u00a0AI, Reich\u00a0C et\u00a0al (2008) Benefit evaluation in vitiligo treatment: development and validation of a\u00a0patient-defined outcome questionnaire. Dermatology 217:101\u2013106","journal-title":"Dermatology"},{"key":"5312_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1365-2249.1996.d01-727.x","volume":"105","author":"E Baharav","year":"1996","unstructured":"Baharav\u00a0E, Merimski\u00a0O, Shoenfeld\u00a0Y et\u00a0al (1996) Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105:84\u201388","journal-title":"Clin Exp Immunol"},{"key":"5312_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","volume":"156","author":"JM Bae","year":"2020","unstructured":"Bae\u00a0JM, Ju\u00a0HJ, Lee\u00a0RW et\u00a0al (2020) Korean society of vitiligo evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UVB phototherapy. JAMA Dermatol 156:529\u2013537","journal-title":"JAMA Dermatol"},{"key":"5312_CR9","first-page":"51","volume":"17","author":"PN Behl","year":"1972","unstructured":"Behl\u00a0PN, Bhatia\u00a0RK (1972) 400 cases of vitiligo. A\u00a0clinico-therapeutic analysis. Indian J Dermatol 17:51\u201356","journal-title":"Indian J Dermatol"},{"key":"5312_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1346-8138.15743","volume":"48","author":"C Bergqvist","year":"2021","unstructured":"Bergqvist\u00a0C, Ezzedine\u00a0K (2021) Vitiligo: a\u00a0focus on pathogenesis and its therapeutic implications. J\u00a0Dermatol 48:252\u2013270","journal-title":"J Dermatol"},{"key":"5312_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist\u00a0C, Ezzedine\u00a0K (2020) Vitiligo: a\u00a0review. Dermatology 236:571\u2013592","journal-title":"Dermatology"},{"key":"5312_CR12","doi-asserted-by":"crossref","unstructured":"Bibeau K, Pandya AG, Ezzedine K et\u00a0al (2022) Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J\u00a0Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.18257"},{"key":"5312_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/CCID.S151114","volume":"11","author":"R Bidaki","year":"2018","unstructured":"Bidaki\u00a0R, Majidi\u00a0N, Moghadam Ahmadi\u00a0A et\u00a0al (2018) Vitiligo and social acceptance. Clin Cosmet Investig Dermatol 11:383\u2013386","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"5312_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/978-3-662-49544-5_69","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"M B\u00f6hm","year":"2018","unstructured":"B\u00f6hm\u00a0M (2018) St\u00f6rungen der Melaninpigmentierung. In: Plewig\u00a0G, Ruzicka\u00a0T, Kaufmann\u00a0R, Hertl\u00a0M (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer, Berlin, Heidelberg, S\u00a01259\u20131294"},{"key":"5312_CR15","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Schunter\u00a0JA, Fritz\u00a0K et\u00a0al (2022) S1-Leitlinie: diagnostik und therapie der vitiligo. J\u00a0Dtsch Dermatol Ges 20:365\u2013379","journal-title":"J Dtsch Dermatol Ges"},{"key":"5312_CR16","first-page":"45","volume":"14","author":"K Bonotis","year":"2016","unstructured":"Bonotis\u00a0K, Pantelis\u00a0K, Karaoulanis\u00a0S et\u00a0al (2016) Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J\u00a0Dtsch Dermatol Ges 14:45\u201349","journal-title":"J Dtsch Dermatol Ges"},{"key":"5312_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/pde.13517","volume":"35","author":"SD Cadmus","year":"2018","unstructured":"Cadmus\u00a0SD, Lundgren\u00a0AD, Ahmed\u00a0AM (2018) Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: a\u00a0review. Pediatr Dermatol 35:441\u2013447","journal-title":"Pediatr Dermatol"},{"key":"5312_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1159\/000448656","volume":"232","author":"J Catucci Boza","year":"2016","unstructured":"Catucci Boza\u00a0J, Giongo\u00a0N, Machado\u00a0P et\u00a0al (2016) Quality of life impairment in children and adults with vitiligo: a\u00a0cross-sectional study based on dermatology-specific and disease-specific quality of life instruments. Dermatology 232:619\u2013625","journal-title":"Dermatology"},{"key":"5312_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/1346-8138.15290","volume":"47","author":"CY Chen","year":"2020","unstructured":"Chen\u00a0CY, Wang\u00a0WM, Chung\u00a0CH et\u00a0al (2020) Increased risk of psychiatric disorders in adult patients with vitiligo: a\u00a0nationwide, population-based cohort study in Taiwan. J\u00a0Dermatol 47:470\u2013475","journal-title":"J Dermatol"},{"key":"5312_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jdv.18593","volume":"37","author":"PV Chernyshov","year":"2023","unstructured":"Chernyshov\u00a0PV, Tomas-Aragones\u00a0L, Manolache\u00a0L et\u00a0al (2023) Quality of life measurement in vitiligo. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes with external experts. J\u00a0Eur Acad Dermatol Venereol 37:21\u201331","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jaad.2021.02.083","volume":"86","author":"M Condamina","year":"2022","unstructured":"Condamina\u00a0M, Shourick\u00a0J, Seneschal\u00a0J et\u00a0al (2022) Factors associated with perceived stress in patients with vitiligo in the ComPaRe e\u2011cohort. J\u00a0Am Acad Dermatol 86:696\u2013698","journal-title":"J Am Acad Dermatol"},{"key":"5312_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clindermatol.2017.01.001","volume":"35","author":"F Cupertino","year":"2017","unstructured":"Cupertino\u00a0F, Niemeyer-Corbellini\u00a0JP, Ramos\u00a0ESM (2017) Psychosomatic aspects of vitiligo. Clin Dermatol 35:292\u2013297","journal-title":"Clin Dermatol"},{"key":"5312_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jdv.15987","volume":"34","author":"G Dabas","year":"2020","unstructured":"Dabas\u00a0G, Vinay\u00a0K, Parsad\u00a0D et\u00a0al (2020) Psychological disturbances in patients with pigmentary disorders: a\u00a0cross-sectional study. J\u00a0Eur Acad Dermatol Venereol 34:392\u2013399","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","volume":"57","author":"AM Dahir","year":"2018","unstructured":"Dahir\u00a0AM, Thomsen\u00a0SF (2018) Comorbidities in vitiligo: comprehensive review. Int J Dermatol 57:1157\u20131164","journal-title":"Int J Dermatol"},{"key":"5312_CR25","volume-title":"Psychosomatische Dermatologie (Psychodermatologie)","author":"Deutsche Dermatologische Gesellschaft E.\u202fV. (Ddg)","year":"2018","unstructured":"Deutsche Dermatologische Gesellschaft E.\u202fV. (Ddg) (2018) Psychosomatische Dermatologie (Psychodermatologie)"},{"key":"5312_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bjd.16072","volume":"178","author":"K Ezzedine","year":"2018","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V (2018) Vitiligo and quality of life: the dark face of whiteness. Br J Dermatol 178:28\u201329","journal-title":"Br J Dermatol"},{"key":"5312_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V, Jones\u00a0H et\u00a0al (2021) Psychosocial effects of vitiligo: a\u00a0systematic literature review. Am J Clin Dermatol 22:757\u2013774","journal-title":"Am J Clin Dermatol"},{"key":"5312_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V, Whitton\u00a0M et\u00a0al (2015) Vitiligo. Lancet 386:74\u201384","journal-title":"Lancet"},{"key":"5312_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bjd.13839","volume":"173","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine\u00a0K, Grimes\u00a0PE, Meurant\u00a0JM et\u00a0al (2015) Living with vitiligo: results from a\u00a0national survey indicate differences between skin phototypes. Br J Dermatol 173:607\u2013609","journal-title":"Br J Dermatol"},{"key":"5312_CR30","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine\u00a0K, Lim\u00a0HW, Suzuki\u00a0T et\u00a0al (2012) Revised classification\/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res 25:E1\u2013E13","journal-title":"Pigment Cell Melanoma Res"},{"key":"5312_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine\u00a0K, Sheth\u00a0V, Rodrigues\u00a0M et\u00a0al (2015) Vitiligo is not a\u00a0cosmetic disease. J\u00a0Am Acad Dermatol 73:883\u2013885","journal-title":"J Am Acad Dermatol"},{"key":"5312_CR32","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2016.12399","volume":"316","author":"K Ezzedine","year":"2016","unstructured":"Ezzedine\u00a0K, Whitton\u00a0M, Pinart\u00a0M (2016) Interventions for vitiligo. JAMA 316:1708\u20131709","journal-title":"JAMA"},{"key":"5312_CR33","doi-asserted-by":"crossref","unstructured":"Fatima S, Abbas T, Refat MA et\u00a0al (2022) Systemic therapies in vitiligo: a\u00a0review. Int J Dermatol","DOI":"10.1111\/ijd.16114"},{"key":"5312_CR34","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jid.2023.04.013","volume":"143","author":"J Ferguson","year":"2023","unstructured":"Ferguson\u00a0J, Eleftheriadou\u00a0V, Nesnas\u00a0J (2023) Risk of melanoma and nonmelanoma skin cancer in people with vitiligo: United Kingdom population-based cohort study. J\u00a0Invest Dermatol 143:2204\u20132210","journal-title":"J Invest Dermatol"},{"key":"5312_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"ML Frisoli","year":"2020","unstructured":"Frisoli\u00a0ML, Essien\u00a0K, Harris\u00a0JE (2020) Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621\u2013648","journal-title":"Annu Rev Immunol"},{"key":"5312_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","volume":"140","author":"ML Frisoli","year":"2017","unstructured":"Frisoli\u00a0ML, Harris\u00a0JE (2017) Vitiligo: mechanistic insights lead to novel treatments. J\u00a0Allergy Clin Immunol 140:654\u2013662","journal-title":"J Allergy Clin Immunol"},{"key":"5312_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","volume":"4","author":"PE Grimes","year":"2018","unstructured":"Grimes\u00a0PE, Miller\u00a0MM (2018) Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol 4:32\u201337","journal-title":"Int J Womens Dermatol"},{"key":"5312_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0190-9622(96)90718-5","volume":"35","author":"SK Hann","year":"1996","unstructured":"Hann\u00a0SK, Lee\u00a0HJ (1996) Segmental vitiligo: clinical findings in 208 patients. J\u00a0Am Acad Dermatol 35:671\u2013674","journal-title":"J Am Acad Dermatol"},{"key":"5312_CR39","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1038\/d41586-018-07435-5","volume":"563","author":"J Harris","year":"2018","unstructured":"Harris\u00a0J (2018) Vitiligo\u2019s impact is in the eye of the beholder. Nature 563:S99","journal-title":"Nature"},{"key":"5312_CR40","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin\u00a0Y, Andersen\u00a0G, Yorgov\u00a0D et\u00a0al (2016) Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet 48:1418\u20131424","journal-title":"Nat Genet"},{"key":"5312_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41467-019-08337-4","volume":"10","author":"Y Jin","year":"2019","unstructured":"Jin\u00a0Y, Roberts\u00a0GHL, Ferrara\u00a0TM et\u00a0al (2019) Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class\u00a0II HLA expression. Nat Commun 10:391","journal-title":"Nat Commun"},{"key":"5312_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14728214.2020.1712358","volume":"25","author":"P Karagaiah","year":"2020","unstructured":"Karagaiah\u00a0P, Valle\u00a0Y, Sigova\u00a0J et\u00a0al (2020) Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs 25:7\u201324","journal-title":"Expert Opin Emerg Drugs"},{"key":"5312_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2249.1997.4781381.x","volume":"109","author":"EH Kemp","year":"1997","unstructured":"Kemp\u00a0EH, Gawkrodger\u00a0DJ, Watson\u00a0PF et\u00a0al (1997) Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein\u20112 (TRP-2). Clin Exp Immunol 109:495\u2013500","journal-title":"Clin Exp Immunol"},{"key":"5312_CR44","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2230.1996.tb00116.x","volume":"21","author":"G Kent","year":"1996","unstructured":"Kent\u00a0G, Al-Abadie\u00a0M (1996) Factors affecting responses on dermatology life quality index items among vitiligo sufferers. Clin Exp Dermatol 21:330\u2013333","journal-title":"Clin Exp Dermatol"},{"key":"5312_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4103\/idoj.IDOJ_14_18","volume":"10","author":"RS Kota","year":"2019","unstructured":"Kota\u00a0RS, Vora\u00a0RV, Varma\u00a0JR et\u00a0al (2019) Study on assessment of quality of life and depression in patients of vitiligo. Indian Dermatol Online\u00a0J 10:153\u2013157","journal-title":"Indian Dermatol Online J"},{"key":"5312_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000350010","volume":"44","author":"C Kruger","year":"2013","unstructured":"Kruger\u00a0C, Schallreuter\u00a0KU (2013) Cumulative life course impairment in vitiligo. Curr Probl Dermatol 44:102\u2013117","journal-title":"Curr Probl Dermatol"},{"key":"5312_CR47","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly\u00a0E, Lu\u00a0PD, Borovicka\u00a0JH et\u00a0al (2013) Development and validation of a\u00a0vitiligo-specific quality-of-life instrument (VitiQoL). J\u00a0Am Acad Dermatol 69:e11\u201318","journal-title":"J Am Acad Dermatol"},{"key":"5312_CR48","first-page":"504","volume":"99","author":"A Maamri","year":"2021","unstructured":"Maamri\u00a0A, Badri\u00a0T (2021) Sexual disorders in patients with vitiligo. Tunis Med 99:504\u2013505","journal-title":"Tunis Med"},{"key":"5312_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/CLEP.S304155","volume":"13","author":"N Mohr","year":"2021","unstructured":"Mohr\u00a0N, Petersen\u00a0J, Kirsten\u00a0N et\u00a0al (2021) Epidemiology of vitiligo\u2014a dual population-based approach. Clin Epidemiol 13:373\u2013382","journal-title":"Clin Epidemiol"},{"key":"5312_CR50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ad.2017.03.007","volume":"108","author":"MA Morales-Sanchez","year":"2017","unstructured":"Morales-Sanchez\u00a0MA, Vargas-Salinas\u00a0M, Peralta-Pedrero\u00a0ML et\u00a0al (2017) Impact of vitiligo on quality of life. Actas Dermosifiliogr 108:637\u2013642","journal-title":"Actas Dermosifiliogr"},{"key":"5312_CR51","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/bjd.15933","volume":"177","author":"B Morrison","year":"2017","unstructured":"Morrison\u00a0B, Burden-Teh\u00a0E, Batchelor\u00a0JM et\u00a0al (2017) Quality of life in people with vitiligo: a\u00a0systematic review and meta-analysis. Br J Dermatol 177:e338\u2013e339","journal-title":"Br J Dermatol"},{"key":"5312_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/0019-5154.174048","volume":"61","author":"SR Narahari","year":"2016","unstructured":"Narahari\u00a0SR, Prasanna\u00a0KS, Aggithaya\u00a0MG et\u00a0al (2016) Dermatology life quality index does not reflect quality of life status of Indian vitiligo patients. Indian J Dermatol 61:99\u2013100","journal-title":"Indian J Dermatol"},{"key":"5312_CR53","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi\u00a0O, Grainge\u00a0MJ, Hong\u00a0L et\u00a0al (2018) The prevalence of psychological comorbidity in people with vitiligo: a\u00a0systematic review and meta-analysis. Br J Dermatol 178:863\u2013878","journal-title":"Br J Dermatol"},{"key":"5312_CR54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-7525-1-58","volume":"1","author":"D Parsad","year":"2003","unstructured":"Parsad\u00a0D, Dogra\u00a0S, Kanwar\u00a0AJ (2003) Quality of life in patients with vitiligo. Health Qual Life Outcomes 1:58","journal-title":"Health Qual Life Outcomes"},{"key":"5312_CR55","doi-asserted-by":"crossref","unstructured":"Picardo M, Huggins RH, Jones H et\u00a0al (2022) The humanistic burden of vitiligo: a\u00a0systematic literature review of quality-of-life outcomes. J\u00a0Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.18129"},{"key":"5312_CR56","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2307\/2137152","volume":"32","author":"JR Porter","year":"1991","unstructured":"Porter\u00a0JR, Beuf\u00a0AH (1991) Racial variation in reaction to physical stigma: a\u00a0study of degree of disturbance by vitiligo among black and white patients. J\u00a0Health Soc Behav 32:192\u2013204","journal-title":"J Health Soc Behav"},{"key":"5312_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.det.2020.08.011","volume":"39","author":"J Pun","year":"2021","unstructured":"Pun\u00a0J, Randhawa\u00a0A, Kumar\u00a0A et\u00a0al (2021) The impact of vitiligo on quality of life and psychosocial well-being in a\u00a0nepalese population. Dermatol Clin 39:117\u2013127","journal-title":"Dermatol Clin"},{"key":"5312_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","volume":"161","author":"MA Radtke","year":"2009","unstructured":"Radtke\u00a0MA, Schafer\u00a0I, Gajur\u00a0A et\u00a0al (2009) Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 161:134\u2013139","journal-title":"Br J Dermatol"},{"key":"5312_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000275657","volume":"220","author":"MA Radtke","year":"2010","unstructured":"Radtke\u00a0MA, Schafer\u00a0I, Gajur\u00a0AI et\u00a0al (2010) Clinical features and treatment outcomes of vitiligo from the patients\u2019 perspective: results of a\u00a0national survey in Germany. Dermatology 220:194\u2013200","journal-title":"Dermatology"},{"key":"5312_CR60","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1468-3083.2007.02228.x","volume":"21","author":"N Rezaei","year":"2007","unstructured":"Rezaei\u00a0N, Gavalas\u00a0NG, Weetman\u00a0AP et\u00a0al (2007) Autoimmunity as an aetiological factor in vitiligo. J\u00a0Eur Acad Dermatol Venereol 21:865\u2013876","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues\u00a0M, Ezzedine\u00a0K, Hamzavi\u00a0I et\u00a0al (2017) Current and emerging treatments for vitiligo. J\u00a0Am Acad Dermatol 77:17\u201329","journal-title":"J Am Acad Dermatol"},{"key":"5312_CR62","first-page":"688","volume":"17","author":"AK Rzepecki","year":"2018","unstructured":"Rzepecki\u00a0AK, Mclellan\u00a0BN, Elbuluk\u00a0N (2018) Beyond traditional treatment: the importance of psychosocial therapy in vitiligo. J\u00a0Drugs Dermatol 17:688\u2013691","journal-title":"J Drugs Dermatol"},{"key":"5312_CR63","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40257-016-0172-x","volume":"17","author":"A Salman","year":"2016","unstructured":"Salman\u00a0A, Kurt\u00a0E, Topcuoglu\u00a0V et\u00a0al (2016) Social anxiety and quality of life in vitiligo and acne patients with facial involvement: a\u00a0cross-sectional controlled study. Am J Clin Dermatol 17:305\u2013311","journal-title":"Am J Clin Dermatol"},{"key":"5312_CR64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/JID.2015.398","volume":"136","author":"C Salzes","year":"2016","unstructured":"Salzes\u00a0C, Abadie\u00a0S, Seneschal\u00a0J et\u00a0al (2016) The Vitiligo Impact Patient Scale (VIPs): development and validation of a\u00a0vitiligo burden assessment tool. J\u00a0Invest Dermatol 136:52\u201358","journal-title":"J Invest Dermatol"},{"key":"5312_CR65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/0092623X.2015.1010678","volume":"42","author":"D Sarhan","year":"2016","unstructured":"Sarhan\u00a0D, Mohammed\u00a0GF, Gomaa\u00a0AH et\u00a0al (2016) Female genital dialogues: female genital self-image, sexual dysfunction, and quality of life in patients with vitiligo with and without genital affection. J\u00a0Sex Marital Ther 42:267\u2013276","journal-title":"J Sex Marital Ther"},{"key":"5312_CR66","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jocd.13807","volume":"20","author":"S Savas Erdogan","year":"2021","unstructured":"Savas Erdogan\u00a0S, Falay\u00a0GT, Dogan\u00a0B (2021) Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: a\u00a0cross-sectional controlled study. J\u00a0Cosmet Dermatol 20:2232\u20132239","journal-title":"J Cosmet Dermatol"},{"key":"5312_CR67","doi-asserted-by":"publisher","first-page":"6879412","DOI":"10.1155\/2019\/6879412","volume":"2019","author":"NS Sawant","year":"2019","unstructured":"Sawant\u00a0NS, Vanjari\u00a0NA, Khopkar\u00a0U (2019) Gender differences in depression, coping, stigma, and quality of life in patients of vitiligo. Dermatol Res Pract 2019:6879412","journal-title":"Dermatol Res Pract"},{"key":"5312_CR68","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1468-3083.2006.01897.x","volume":"21","author":"G Schmid-Ott","year":"2007","unstructured":"Schmid-Ott\u00a0G, Kunsebeck\u00a0HW, Jecht\u00a0E et\u00a0al (2007) Stigmatization experience, coping and sense of coherence in vitiligo patients. J\u00a0Eur Acad Dermatol Venereol 21:456\u2013461","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR69","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2147\/CCID.S265349","volume":"13","author":"N Silpa-Archa","year":"2020","unstructured":"Silpa-Archa\u00a0N, Pruksaeakanan\u00a0C, Angkoolpakdeekul\u00a0N et\u00a0al (2020) Relationship between depression and quality of life among vitiligo patients: a\u00a0self-assessment questionnaire-based study. Clin Cosmet Investig Dermatol 13:511\u2013520","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"5312_CR70","first-page":"672","volume":"20","author":"ZI Smith","year":"2021","unstructured":"Smith\u00a0ZI, Wang\u00a0JF, Elbuluk\u00a0N et\u00a0al (2021) A multi-centered case-control study of vitiligo support groups and quality of life. J\u00a0Drugs Dermatol 20:672\u2013675","journal-title":"J Drugs Dermatol"},{"key":"5312_CR71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00926230600998482","volume":"33","author":"M Sukan","year":"2007","unstructured":"Sukan\u00a0M, Maner\u00a0F (2007) The problems in sexual functions of vitiligo and chronic urticaria patients. J\u00a0Sex Marital Ther 33:55\u201364","journal-title":"J Sex Marital Ther"},{"key":"5312_CR72","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/jdv.15297","volume":"32","author":"A Taieb","year":"2018","unstructured":"Taieb\u00a0A, Meurant\u00a0JM (2018) Should we prioritize psychological interventions in the management of vitiligo? J\u00a0Eur Acad Dermatol Venereol 32:2053\u20132054","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5312_CR73","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ced.15010","volume":"47","author":"YH Wu","year":"2021","unstructured":"Wu\u00a0YH, Chou\u00a0CL, Chang\u00a0HC (2021) Risk of skin cancer after ultraviolet phototherapy in patients with vitiligo: a\u00a0systematic review and meta-analysis. Clin Exp Dermatol 47:692\u2013711","journal-title":"Clin Exp Dermatol"},{"key":"5312_CR74","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/bjd.15936","volume":"177","author":"Y Yang","year":"2017","unstructured":"Yang\u00a0Y, Zapata\u00a0L, Rodgers\u00a0C et\u00a0al (2017) Quality of life in patients with vitiligo using the short form-36. Br J Dermatol 177:1764\u20131766","journal-title":"Br J Dermatol"},{"key":"5312_CR75","doi-asserted-by":"crossref","unstructured":"Yang YT, Hsu CH, Wang YF et\u00a0al (2022) Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: a\u00a0hospital-based case control study in Taiwan. Int J Environ Res Public Health 19:","DOI":"10.3390\/ijerph19116741"},{"key":"5312_CR76","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ced.14511","volume":"46","author":"D Yucel","year":"2021","unstructured":"Yucel\u00a0D, Sener\u00a0S, Turkmen\u00a0D et\u00a0al (2021) Evaluation of the dermatological life quality index, sexual dysfunction and other psychiatric diseases in patients diagnosed with vitiligo with and without genital involvement. Clin Exp Dermatol 46:669\u2013674","journal-title":"Clin Exp Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05312-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05312-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05312-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:02:21Z","timestamp":1714636941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05312-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5312"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05312-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"24 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Augustin hat Vortrags- und Beratungshonorare von Incyte und Pfizer erhalten. M.\u00a0B\u00f6hm hat Vortrags- und Beratungshonorare von Incyte, AbbVie und Pfizer erhalten. C.\u00a0Gewiss und N.\u00a0Ben-Anaya geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}